Icant difference in the distribution of histologies, primaries and sta…

Icant difference in the distribution of histologies, primaries and staging between males and females. However, in the SEER database male patients were more likely to have metastasis at presentation, than female patients, in a statistically significant way [15]. We were able to detect in our tumors local and vascular infiltration two wellestablished features of malignant behavior with adverse prognostic significance [5]. As long term data of our cohort is not yet matured we cannot comment on the impact of these features on the survival of our patients. With respect Staurosporine to diagnostic imaging, in our population imaging with internationally recommended techniques such as somatostatin receptor PET/CT imaging with Gallium-68 and endoscopic ultrasound (EUS) is either unavailable (68Ga) or accessible in very few sites (EUS). In our study octreoscan was less sensitive compared to other procedures such as computed tomography. This is in line with an earlier study by our group showing that octreoscan compared to conventional imaging such as ultrasound and CT is less sensitive for the detection of liver metastases [28]. The most commonly applied therapy in our cohort was somatostatin analogs (SSA), octreotide 30 mg LAR and lanreotide 120 mg Autogel, both with an established role in the symptom and tumor control of patients with well and moderately differentiated NENs [29?1]. Recently, in the CLARINET trial, lanreotide 120 mgAutogel was established for its anti tumoral effect in both pancreatic and gastroenteric locally advanced or metastatic neuroendocrine tumors with Ki-67 up to 10 . In this registry, the response was documented as improvement, stabilization or deterioration of the symptoms, without the use of the RECIST criteria, since this was out of the scope of the registry. Similarly to the previously published studies, our findings indicate an equal role of the different SSAs in the control of NEN symptoms. Other therapies applied in our patients with Ki-67 LI 20 were treated with systemic chemotherapy comprising cisplatin/carboplatin and etoposide doublets according to established evidence [36]. Limitations of our study include a) the fact that not all NENs diagnosed in our country between October 2010 and November 2012 were included in the present registry and b) the lack of information on survival, progressive free survival, recurrences and new metastases. As long term data of our cohort is not yet matured we cannot comment on the impact of our findings on the evolution of the disease in general and on overall survival.Conclusions We present for the first time the results of a Greek NET registry that includes NEN from a variety of primary sites. Our results indicate some differences in the occurrence of NENs reported from registries of other European countries and the USA. It is thus important to develop national registries for the precise description of the incidence and the handling of NENs and the possible application of the PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/17139194 findings in prevention and pharmacoeconomics. Based on the reported occurrence of NENs and the variations in incidence observed in the literature it is important that each country develops a national registry for the recording of the incidence and clinico-pathologic characteristic.